^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Salivary Gland Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Excerpt:
...- HER2 amplification as determined by FISH (HER2/CEP 17 ratio greater than or equal to 2.0 or HER2 mean copy number greater than or equal to 4.0)...
Trial ID:
Source:
Title:
Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
Published date:
05/25/2023
Excerpt:
Ado-trastuzumab emtansine showed promising efficacy in patients with HER2 amplified lung and salivary gland cancers as identified by NGS, meeting the primary endpoint.
DOI:
10.1200/JCO.2023.41.16_suppl.3025
Trial ID:
Source:
Title:
A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
Published date:
05/16/2018
Excerpt:
Ado-trastuzumab emtansine showed efficacy in patients with HER2 amplified lung, endometrial, salivary gland, biliary tract and ovarian cancers as identified by NGS.
DOI:
10.1200/JCO.2018.36.15_suppl.2502
Trial ID:
Source:
Title:
PDF [581 KB] Figures Save Share Reprints Request Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Excerpt:
Thirty-eight patients with a tumor ERBB2 CN of >7 were assigned and enrolled on this subprotocol arm….Some reduction in tumor size was seen in 17 patients (Figure 3). Of the seven patients with more than 30% reduction in the sum of diameters of measurable tumors, two patients with salivary gland cancers (one patient each with mucoepidermoid carcinoma of the parotid gland and squamous cell carcinoma of the parotid gland) were confirmed to be partial responders...T-DM1 was well tolerated.
DOI:
https://doi.org/10.1093/annonc/mdz291
Trial ID:
Source:
Title:
Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.
Published date:
05/16/2018
Excerpt:
3/37 (8.1%, 90% CI 2.2%-19.6%) had a confirmed partial response including 1 patient each with salivary duct ca of parotid gland,...T-DM1 was well tolerated. Clinical activity was observed in HER2 amp non breast and gastric/GEJ adenoca pts…
DOI:
10.1200/JCO.2018.36.15_suppl.100
Trial ID:
